← Leaderboards
Judith S. Currier
University Of California Los Angeles
$525,401,794
Attributed
$1,001,251,432
Total exposure
44
Grants
32
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $224.2M · FY2005–25$250M$187.5M$125M$62.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,012,310,167 · 44
CDC$36,020 · 1
By mechanism
UM1$970,794,301 · 2
U01$18,981,449 · 2
P30$11,690,311 · 2
R01$4,030,053 · 1
M01$2,277,743 · 34
T32$2,153,740 · 1
Top collaborators
- Joseph J. Eron36 shared
- Pamina Mae Gorbach6 shared
- Lashonda Spencer6 shared
- Jerome A. Zack6 shared
- Raphael J Landovitz5 shared
- James H Stein5 shared
- Daniel R Kuritzkes4 shared
Most similar at University Of California Los Angeles
Same institution · by research overlap
- Steven-Huy B Han$3,380,303
- Tram Thuy Tran$928,454
Others in their field
Top investigators on “Research Personnel”
- David Heimbrook · Leidos Biomedical Research, Inc.$701,463,488
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Leonard Freedman · Leidos Biomedical Research, Inc.$557,978,666
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David R. Weir · University Of Michigan At Ann Arbor$364,053,504
- Richard K. Wilson · Washington University$270,665,532
Research focus
Research PersonnelClinical ResearchHiv InfectionsDesignClinical TrialsPreventPreventionResourcesFundingAreaLeadershipLos AngelesAids Clinical Trial GroupCollaborationsAntiretroviral TherapyPersonsComorbidityInfectionLaboratoriesMultidisciplinaryTrainingMorbidity - Disease RateProtocols DocumentationTuberculosis
Grant awards (159)
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$36,436,959
UM1 · FY2025 · AI · contact PI
UCLA AIDS Prevention and Treatment Clinical Trials Unit$3,585,709
UM1 · FY2025 · AI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections-A5407 Third Supplement$2,991,790
UM1 · FY2025 · AI · contact PI
UCLA-CDU CFAR$2,250,002
P30 · FY2025 · AI · contact PI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections- Small Clinical Trials Unit (SCTU)$2,203,379
UM1 · FY2025 · AI · contact PI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$976,570
UM1 · FY2025 · AI · contact PI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$134,778
UM1 · FY2025 · AI · contact PI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$127,198
UM1 · FY2025 · AI · contact PI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$115,333
UM1 · FY2025 · AI · contact PI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$54,841
UM1 · FY2025 · AI · contact PI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$53,686
UM1 · FY2025 · AI · contact PI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$37,674
UM1 · FY2025 · AI · contact PI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$30,996
UM1 · FY2025 · AI · contact PI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$28,251
UM1 · FY2025 · AI · contact PI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$27,666
UM1 · FY2025 · AI · contact PI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$1
UM1 · FY2025 · AI · contact PI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$1
UM1 · FY2025 · AI · contact PI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$38,497,989
UM1 · FY2024 · AI · contact PI
UCLA AIDS Prevention and Treatment Clinical Trials Unit$3,954,316
UM1 · FY2024 · AI · contact PI
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections$2,801,829
UM1 · FY2024 · AI · contact PI
UCLA-CDU CFAR$1,950,002
P30 · FY2024 · AI
Evaluating the Relationship Between Age and HIV-1 Persistence$375,973
UM1 · FY2024 · AI · contact PI
Examining Immune Senescence in PLWH and HCV, utilizing the ACTG BIRTH Cohort samples$370,632
UM1 · FY2024 · AI · contact PI
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections$261,226
UM1 · FY2024 · AI · contact PI
UCLA-CDU CFAR$151,916
P30 · FY2024 · AI
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections$76,222,582
UM1 · FY2023 · AI · contact PI
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections$39,807,800
UM1 · FY2023 · AI · contact PI
UCLA AIDS Prevention and Treatment Clinical Trials Unit$3,794,297
UM1 · FY2023 · AI · contact PI
UCLA-CDU CFAR$3,209,540
P30 · FY2023 · AI
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections$2,500,001
UM1 · FY2023 · AI · contact PI
UCLA-CDU CFAR$527,698
P30 · FY2023 · AI
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/$71,500,000
UM1 · FY2022 · AI · contact PI
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections$37,136,690
UM1 · FY2022 · AI · contact PI
A5418 MPX-TPOXX Study Supplement$17,327,975
UM1 · FY2022 · AI · contact PI
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections$10,000,000
UM1 · FY2022 · AI · contact PI
CoVPN 3008 A Phase 3, Multi-Center, Randomized, Efficacy Study of COVID-19 mRNA Vaccine in Regions with SARS-CoV-2 Variants of Concern$7,007,011
UM1 · FY2022 · AI · contact PI
UCLA AIDS Prevention and Treatment Clinical Trials Unit$4,384,228
UM1 · FY2022 · AI · contact PI
UCLA-CDU CFAR$3,005,597
P30 · FY2022 · AI
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections$44,503,132
UM1 · FY2021 · AI · contact PI
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections$40,164,858
UM1 · FY2021 · AI · contact PI
AIDS Clinical Trials Group for Research on Therapeutics for HIV and Related Infections$20,566,378
UM1 · FY2021 · AI · contact PI
CoVPN 3502 / ACTIV-2/A5401$19,807,516
UM1 · FY2021 · AI · contact PI
UCLA AIDS Prevention and Treatment Clinical Trials Unit$5,828,214
UM1 · FY2021 · AI · contact PI
PPE Request$935,415
S10 · FY2021 · AI · contact PI
Postdoctoral Training in Global AIDS Prevention Research$100,565
T32 · FY2021 · MH · contact PI
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/$181,942,638
UM1 · FY2020 · AI · contact PI
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/$36,091,763
UM1 · FY2020 · AI · contact PI
UCLA AIDS Prevention and Treatment Clinical Trials Unit$4,062,344
UM1 · FY2020 · AI · contact PI
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy of Hydroxychloroquine and Azithromycin to Prevent Hospitalization or Death in Persons with COVID-19$1,259,902
UM1 · FY2020 · AI · contact PI
Postdoctoral Training in Global AIDS Prevention Research$540,132
T32 · FY2020 · MH · contact PI
UCLA AIDS Prevention and Treatment Clinical Trials Unit$300,001
UM1 · FY2020 · AI · contact PI
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/$32,273,937
UM1 · FY2019 · AI · contact PI
UCLA AIDS Prevention and Treatment Clinical Trials Unit$4,522,429
UM1 · FY2019 · AI · contact PI
Postdoctoral Training in Global AIDS Prevention Research$517,828
T32 · FY2019 · MH · contact PI
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/$60,609,395
UM1 · FY2018 · AI
UCLA AIDS Prevention and Treatment Clinical Trials Unit$1,904,461
UM1 · FY2018 · AI · contact PI
Postdoctoral Training in Global AIDS Prevention Research$255,461
T32 · FY2018 · MH · contact PI
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/$56,989,695
UM1 · FY2017 · AI
UCLA AIDS Prevention and Treatment Clinical Trials Unit$1,641,447
UM1 · FY2017 · AI · contact PI
Postdoctoral Training in Global AIDS Prevention Research$318,917
T32 · FY2017 · MH · contact PI
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/$35,812,481
UM1 · FY2016 · AI
UCLA AIDS Prevention and Treatment Clinical Trials Unit$1,795,330
UM1 · FY2016 · AI · contact PI
Postdoctoral Training in Global AIDS Prevention Research$420,837
T32 · FY2016 · MH · contact PI
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/$46,918,193
UM1 · FY2015 · AI
UCLA AIDS Prevention and Treatment Clinical Trials Unit$1,604,376
UM1 · FY2015 · AI · contact PI
UCLA AIDS Prevention and Treatment Clinical Trials Unit$2,737,442
UM1 · FY2014 · AI · contact PI
UCLA AIDS Prevention and Treatment Clinical Trials Unit$2,494,558
UM1 · FY2013 · AI · contact PI
Optimizing Antiretroviral Therapy in HIV$144,347
K24 · FY2013 · AI · contact PI
UCLA AIDS Prevention and Treatment Clinical Trials Unit$4,216,430
UM1 · FY2012 · AI · contact PI
Prospective Evaluation of Antiviral Therapy and Cardiac Health$679,219
R01 · FY2012 · HL · contact PI
Optimizing Antiretroviral Therapy in HIV$144,347
K24 · FY2012 · AI · contact PI
Clinical Research Facilitation Core$134,684
P30 · FY2012 · AI · contact PI
UCLA AIDS Prevention and Treatment Clinical Trials Unit$1,442,278
U01 · FY2011 · AI · contact PI
Prospective Evaluation of Antiviral Therapy and Cardiac Health$801,848
R01 · FY2011 · HL · contact PI
Clinical Research Facilitation Core$189,401
P30 · FY2011 · AI · contact PI
Optimizing Antiretroviral Therapy in HIV$144,347
K24 · FY2011 · AI · contact PI
UCLA AIDS Prevention and Treatment Clinical Trials Unit$2,462,528
U01 · FY2010 · AI · contact PI
Prospective Evaluation of Antiviral Therapy and Cardiac Health$820,964
R01 · FY2010 · HL · contact PI
UCLA AIDS Prevention and Treatment Clinical Trials Unit$613,809
U01 · FY2010 · AI · contact PI
Optimizing Antiretroviral Therapy in HIV$144,347
K24 · FY2010 · AI · contact PI
Clinical Research Facilitation Core$97,162
P30 · FY2010 · AI · contact PI
A PHASE IV, PROSPECTIVE, RANDOMIZED, OPEN-LABEL EVALUATION OF THE EFFICACY OF$13,450
M01 · FY2010 · RR · contact PI
PHASE II, RANDOMIZED, DOUBLE-BLIND STUDY OF THE SAFETY AND EFFICACY OF SCH 41$4,483
M01 · FY2010 · RR · contact PI
UCLA AIDS Prevention and Treatment Clinical Trials Unit$3,486,794
U01 · FY2009 · AI · contact PI
UCLA AIDS Prevention and Treatment Clinical Trials Unit$1,970,379
U01 · FY2009 · AI · contact PI
Prospective Evaluation of Antiviral Therapy and Cardiac Health$859,156
R01 · FY2009 · HL · contact PI
Optimizing Antiretroviral Therapy in HIV$144,347
K24 · FY2009 · AI · contact PI
Clinical Research Facilitation Core$90,515
P30 · FY2009 · AI · contact PI
A PHASE II/III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF URIDINE$20,558
M01 · FY2009 · RR · contact PI
A PHASE IV, PROSPECTIVE, RANDOMIZED, OPEN-LABEL EVALUATION OF THE EFFICACY OF$16,153
M01 · FY2009 · RR · contact PI
PHASE II, RANDOMIZED, DOUBLE-BLIND STUDY OF THE SAFETY AND EFFICACY OF SCH 41$7,343
M01 · FY2009 · RR · contact PI
UCLA AIDS Prevention and Treatment Clinical Trials Unit$2,327,803
U01 · FY2008 · AI · contact PI
Prospective Evaluation of Antiviral Therapy and Cardiac Health$868,866
R01 · FY2008 · HL · contact PI
A PHASE II/III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF URIDINE$103,656
M01 · FY2008 · RR · contact PI
Clinical Research Facilitation Core$83,794
P30 · FY2008 · AI · contact PI
A PHASE IV, PROSPECTIVE, RANDOMIZED, OPEN-LABEL EVALUATION OF THE EFFICACY OF$19,327
M01 · FY2008 · RR · contact PI
SEX DIFFERENCES IN PHARMACOKINETICS OF LOPINAVIR/RITONAVIR AMONG HIV-1 INFECT$12,296
M01 · FY2008 · RR · contact PI
PHASE II, RANDOMIZED, DOUBLE-BLIND STUDY OF THE SAFETY AND EFFICACY OF SCH 41$5,271
M01 · FY2008 · RR · contact PI
A PILOT STUDY OF THE SAFETY, EFFICACY, AND TOLERABILITY OF EZETIMIBE (ZETIA?)$3,515
M01 · FY2008 · RR · contact PI
STAVUDINE DRUG LEVELS AND THE RISK OF METABOLIC TOXICITY IN PATIENTS RECEIVIN$713
M01 · FY2008 · RR · contact PI
UCLA AIDS Prevention and Treatment Clinical Trials Unit$1,617,872
U01 · FY2007 · AI · contact PI
Metabolic Complication of HIV Infection$145,597
K24 · FY2007 · AI · contact PI
FAT REDISTRIBUTION AND METABOLIC CHANGE IN HIV INFECTION: PROTOCOL 2 (FRAM 2)$29,881
M01 · FY2007 · RR · contact PI
A PILOT STUDY OF THE SAFETY, EFFICACY, AND TOLERABILITY OF EZETIMIBE (ZETIA?)$22,135
M01 · FY2007 · RR · contact PI
A PHASE IV, PROSPECTIVE, RANDOMIZED, OPEN-LABEL EVALUATION OF THE EFFICACY OF$14,386
M01 · FY2007 · RR · contact PI
PHASE II, RANDOMIZED, DOUBLE-BLIND STUDY OF THE SAFETY AND EFFICACY OF SCH 41$9,960
M01 · FY2007 · RR · contact PI
SEX DIFFERENCES IN PHARMACOKINETICS OF LOPINAVIR/RITONAVIR AMONG HIV-1 INFECT$5,535
M01 · FY2007 · RR · contact PI
A PHASE II/III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF URIDINE$3,320
M01 · FY2007 · RR · contact PI
AIDS CLINICAL TRIALS UNIT$1,557,742
U01 · FY2006 · AI · contact PI
Metabolic Complication of HIV Infection$145,597
K24 · FY2006 · AI · contact PI
PHASE II, RANDOMIZED, DOUBLE-BLIND STUDY OF THE SAFETY AND EFFICACY OF SCH 41$59,389
M01 · FY2006 · RR · contact PI
ADULTS AIDS CLINICAL TRIALS GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLR$57,304
M01 · FY2006 · RR · contact PI
STD FACULTY EXPANSION PROGRAM$36,020
R30 · FY2006 · PS · contact PI
FAT REDISTRIBUTION AND METABOLIC CHANGE IN HIV INFECTION: PROTOCOL 2 (FRAM 2)$18,754
M01 · FY2006 · RR · contact PI
A PHASE IV, PROSPECTIVE, RANDOMIZED, OPEN-LABEL EVALUATION OF THE EFFICACY OF$16,669
M01 · FY2006 · RR · contact PI
A PROSPECTIVE OBSERVATIONAL STUDY OF VIROLOGIC AND IMMUNOLOGIC CHANGES IN HIV$4,167
M01 · FY2006 · RR · contact PI
STAVUDINE DRUG LEVELS AND THE RISK OF METABOLIC TOXICITY IN PATIENTS RECEIVIN$1,041
M01 · FY2006 · RR · contact PI
AIDS CLINICAL TRIALS UNIT$1,809,728
U01 · FY2005 · AI
Metabolic Complication of HIV Infection$145,597
K24 · FY2005 · AI
ADULTS AIDS CLINICAL TRIALS GROUP LONGITUDINAL LINKED RANDOMIZED TRIALS (ALLR$57,275
M01 · FY2005 · RR
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF METFORMIN AND ROSIGLI$17,775
M01 · FY2005 · RR
A STUDY INVESTIGATING PLASMA LEVELS OF D-CHIRO-INOSITOL IN PATIENTS WITH HIV$5,267
M01 · FY2005 · RR
A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF ONCE-WEEKLY$4,608
M01 · FY2005 · RR
A PROSPECTIVE OBSERVATIONAL STUDY OF VIROLOGIC AND IMMUNOLOGIC CHANGES IN HIV$1,317
M01 · FY2005 · RR
STAVUDINE DRUGS &RISK METABOLIC TOXICITY: PATS RECV ANTIRETROVIRAL THERAPY:AIDS$658
M01 · FY2005 · RR
STD FACULTY EXPANSION PROGRAM$0
R30 · FY2005 · PS
AIDS CLINICAL TRIALS UNIT$1,692,516
U01 · FY2004 · AI
Metabolic Complication of HIV Infection$145,597
K24 · FY2004 · AI
Adults AIDS Clinical Trials Group Longitudinal Linked Randomized Trials (ALLR...$43,234
M01 · FY2004 · RR
Randomized, Double-Blind, Placebo-Controlled Study of$25,324
M01 · FY2004 · RR
Study Investigating plasma levels of D-chiro-inositol$16,059
M01 · FY2004 · RR
PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED$5,559
M01 · FY2004 · RR
STAVUDINE DRUG LEVELS AND THE RISK OF METABOLIC TOXICITY IN PATIENTS RECEIVIN...$3,089
M01 · FY2004 · RR
PILOT STUDY OF THE SAFETY, EFFICACY, AND TOLERABILITY$1,236
M01 · FY2004 · RR
STD FACULTY EXPANSION PROGRAM$0
R30 · FY2004 · PS
Metabolic Complication of HIV Infection$143,032
K24 · FY2003 · AI
STD FACULTY EXPANSION PROGRAM$0
R30 · FY2003 · PS
PHASE I/II TRIAL OF NANDROLONE DECANOATE IN WOMEN W/ HIV ASSOCIATED WEIGHT LOSS$0
M01 · FY2002 · RR
VIRACEPT (BID) AND SANQUINAVIR (BID) COMPARED WITH TID DOSING IN HIV$0
M01 · FY2002 · RR
24 WEEK STUDY OF INDINAVIR SULFATE 800 MG Q8H VERSUS 1200 MG Q12H$0
M01 · FY2002 · RR
ACTG365--STEADY STATE PK INTERACTION STUDY OF INDINAVIR &RIFABUTIN$0
M01 · FY2002 · RR
PHASE II, RANDOMIZED TRIAL OF AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR$207,266
M01 · FY2001 · RR
PHASE II, RANDOMIZED TRIAL OF AMPRENAVIR AS PART OF DUAL PROTEASE INHIBITOR$207,266
M01 · FY2001 · RR
ACTG365--STEADY STATE PK INTERACTION STUDY OF INDINAVIR &RIFABUTIN$155,764
M01 · FY2001 · RR
VIRACEPT (BID) AND SANQUINAVIR (BID) COMPARED WITH TID DOSING IN HIV$155,764
M01 · FY2001 · RR
PHASE I/II TRIAL OF NANDROLONE DECANOATE IN WOMEN W/ HIV ASSOCIATED WEIGHT LOSS$155,764
M01 · FY2001 · RR
24 WEEK STUDY OF INDINAVIR SULFATE 800 MG Q8H VERSUS 1200 MG Q12H$155,764
M01 · FY2001 · RR
24 WEEK STUDY OF INDINAVIR SULFATE 800 MG Q8H VERSUS 1200 MG Q12H$0
M01 · FY2001 · RR
VIRACEPT (BID) AND SANQUINAVIR (BID) COMPARED WITH TID DOSING IN HIV$0
M01 · FY2001 · RR
ACTG365--STEADY STATE PK INTERACTION STUDY OF INDINAVIR &RIFABUTIN$0
M01 · FY2001 · RR
PHASE I/II TRIAL OF NANDROLONE DECANOATE IN WOMEN W/ HIV ASSOCIATED WEIGHT LOSS$0
M01 · FY2001 · RR
24 WEEK STUDY OF INDINAVIR SULFATE 800 MG Q8H VERSUS 1200 MG Q12H$155,764
M01 · FY2000 · RR
ACTG365--STEADY STATE PK INTERACTION STUDY OF INDINAVIR &RIFABUTIN$155,764
M01 · FY2000 · RR
VIRACEPT (BID) AND SANQUINAVIR (BID) COMPARED WITH TID DOSING IN HIV$155,764
M01 · FY2000 · RR
PHASE I/II TRIAL OF NANDROLONE DECANOATE IN WOMEN W/ HIV ASSOCIATED WEIGHT LOSS$35,553
M01 · FY2000 · RR
24 WEEK STUDY OF INDINAVIR SULFATE 800 MG Q8H VERSUS 1200 MG Q12H$35,553
M01 · FY2000 · RR
ACTG365--STEADY STATE PK INTERACTION STUDY OF INDINAVIR &RIFABUTIN$35,553
M01 · FY2000 · RR
VIRACEPT (BID) AND SANQUINAVIR (BID) COMPARED WITH TID DOSING IN HIV$35,497
M01 · FY2000 · RR
PHASE I/II TRIAL OF NANDROLONE DECANOATE IN WOMEN W/ HIV ASSOCIATED WEIGHT LOSS$0
M01 · FY2000 · RR